Cumberland Pharmaceuticals Inc.

Good afternoon and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I would now like to turn it over to Emily Kent, Account Manager at the Dalton Agency, who handles Cumberland's communications. Emily, please proceed.

Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its second quarter financial results. The release also provided an operational update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. Management will share an overview of those financial results during today's call. They'll also provide an overall company update, including a discussion of Cumberland's brand, pipeline, and partners. Participating in today's call are A.J. Kazemi, Cumberland's Chief Executive Officer, along with Todd Anthony, Vice President, Organizational Development, and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions, and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's Form 10-K and any additional updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product website, and you can find links to those sites on the corporate site at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we'll be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call if you prefer. With that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Kazemi.

Thank you, Emily, and good afternoon, everyone. We appreciate you joining us today. As Emily mentioned, during the call, we'll provide a review of our financial results for the second quarter, and we'll also discuss the key developments that have occurred during the period. So let's get started. We've enjoyed a strong first half of the year. There were a series of positive developments during the second quarter, which we'll discuss today, that bolster our optimistic view about the company's future. Earlier this year, we announced positive top-line results from the Phase II study evaluating our iFitraBrand product candidate in patients with Duchenne muscular dystrophy, or DMD. In June, those breakthrough findings were presented at the Parent Project Muscular Dystrophy Annual Conference, and they demonstrated that high-dose ifitriban delivered a 5.4% improvement in the cardiac functions in the patients with DMD. The June presentation also included additional biomarker data indicating reduced cardiac damage, which correlated with the clinical findings. These results position ifitriban as a potential treatment for DMD cardiomyopathy the leading cause of death in these patients, and a critical unmet medical need affecting 90% of DMD patients by age 18. The fight DMD study findings were previously selected for a late-breaking presentation in March at the Muscular Dystrophy Association's clinical and scientific conference, which underscored a significant interest in our approach. In June we completed the comprehensive analysis of the trial results. We prepared our clinical study report and then we submitted that report to the FDA. We followed with a request for an end of phase two meeting. We're very appreciative of the FDA's prompt response and we are scheduled to meet with them this fall to discuss our clinical program and also discuss the development pathway forward. Meanwhile, we previously shared that our potential antibiotic Vibative received approval from the regulatory authorities in China. That milestone provides us with access to the world's second largest pharmaceutical market, and we're now preparing to support the launch of Vibative there. We also shared a new partnership with Saudi-based Tabuk Pharmaceuticals to introduce Vibative into the Middle East. We began shipping by that of there and we've completed the training required to launch the product in that country. Turning to our second quarter financial results, I'm pleased to report our portfolio of FDA approved brands delivered combined revenues of $10.8 million during the quarter, a 10% increase over the same period last year. Year-end revenues for the first six months of the year totaled $22.6 million, a 23% increase over the prior year period. Adjusted earnings for the second quarter were $.4 million and for the first half of this year, adjusted earnings were $2.8 million, or 18 cents a share, up significantly from the same period last year. In addition, Our business generated $4.7 million in cash flow from operations during the first six months of 2025. On our balance sheet, we held $68 million in total assets, including $16 million in cash and cash equivalents. Liabilities were $40 million, and shareholders' equity totaled $28 million all at the end of the quarter. So, with that overview, And now I'd like to turn to Todd Anthony, Cumberland's Vice President, Organizational Development, to discuss with our brands and our sales organization. Todd?